Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, August 28, 2014
Technology Networks
 
Register | Sign in
Home Page > Posters
  Posters

Building Flexibility ino Phase I Protocols and Early Clinical Development Programs
The transition of a drug candidate into Phase I and other early drug development programs is undergoing considerable examination and change. This has largely been brought about by commercial and scientific drivers to reduce attrition rates coupled with an evolving regulatory environment, all of which encourage the pharmaceutical industry to build both scientific focus and flexibility into the drug development program.

Date Posted: 19/06/2008
ePosters.net Ref: EP


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Cancer-Fighting Drugs Might Also Stop Malaria Early
A number of compounds have been identified which could be used to fight malaria.
NIH Announces the Launch of 3 Integrated Precision Medicine Trials
ALCHEMIST is for patients with certain types of early-stage lung cancer.
Cancer Leaves a Common Fingerprint on DNA
Chemical alterations to genes appear key to tumor development.
Researchers Obtain Key Insights into How the Internal Body Clock is Tuned
New way to regulate internal body clocks by long non-coding RNA.
Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy
A predictive marker discovered by scientists at A*STAR and NUS could help doctors classify breast cancer patients for more effective treatment.
Computer Model Reveals Cancer's Energy Source
Findings focused on the energy-making process in cancer cells known as the Warburg Effect.
Immune Cells get Cancer-Fighting Boost From Nanomaterials
Yale researchers used bundled carbon nanotubes to incubate cytotoxic T cells.
New Ways to Treat Solid Tumours
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumour effects.
Gene Likely to Promote Childhood Cancers Pinpointed
CRI Researchers have identified a gene that contributes to the development of several childhood cancers, in a study conducted with mice designed to model the cancers.
New Analysis Reveals Tumor Weaknesses
Identifying epigenetic markers in cancer cells could improve patient treatment.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv